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Spatially offset Raman spectroscopy for
biomedical applications†
Fay Nicolson, a Moritz F. Kircher, ab Nick Stone *cd and Pavel Matousek *e
In recent years, Raman spectroscopy has undergone major advancements in its ability to probe deeply through
turbid media such as biological tissues. This progress has been facilitated by the advent of a range of specialist
techniques based around spatially offset Raman spectroscopy (SORS) to enable non-invasive probing of living
tissue through depths of up to 5 cm. This represents an improvement in depth penetration of up to two orders
of magnitude compared to what can be achieved with conventional Raman methods. In combination with
the inherently high molecular specificity of Raman spectroscopy, this has therefore opened up entirely
new prospects for a range of new analytical applications across multiple fields including medical diagnosis
and disease monitoring. This article discusses SORS and related variants of deep Raman spectroscopy such as
transmission Raman spectroscopy (TRS), micro-SORS and surface enhanced spatially offset Raman
spectroscopy (SESORS), and reviews the progress made in this field during the past 5 years including advances in
non-invasive cancer diagnosis, monitoring of neurotransmitters, and assessment of bone disease.
Introduction
A number of medical conditions such as cancer and bone
disorders are accompanied by significant chemical alterations
in the composition of associated cells and tissues. These
changes, however, facilitate their ability to be detected using
chemically sensitive and specific analytical methods such as
Raman spectroscopy. For the widest and easiest applicability,
these approaches should be non-invasive, provide adequate
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sensitivity despite rapid acquisition, possess high accuracy, and
be accessible at moderate costs.1 Currently, the most widely
applied imaging approaches utilized in the clinic are computed
tomography (CT), magnetic resonance imaging (MRI), positron
emission tomography (PET), and ultrasound. Although these
established imaging modalities are well suited to a range of
medical applications, they are associated with at least one of
the following limitations: high cost, e.g. MRI and PET; involve
the use of ionising radiation, e.g. CT and PET; or provide
inadequate molecularly specific information, e.g. CT, MRI and
ultrasound.1,2
In this context Raman spectroscopy can offer high molecular
specificity, rapid application as well as low to moderate cost. In
addition, Raman spectroscopy avoids the safety concerns asso-
ciated with ionising radiation, thus providing attractive, com-
plementary alternatives to traditional imaging modalities.
However, traditional Raman imaging is limited in its ability
to probe deeper seated tissue at depth beyond near-surface
tissue layers (typically several hundred micrometres deep to
mm with ‘‘surface enhanced Raman scattering’’ (SERS) agents).
Subcutaneous Raman needle probes have been developed for
this purpose,3,4 but of course can only be employed invasively
in non-sensitive tissues. Many clinical applications are more suited
to non-invasive approaches, thus preventing Raman spectroscopy
from being applied to diagnostic applications which require deeper
scanning capabilities. The advent of ‘‘Spatially Offset Raman
Spectroscopy’’ (SORS) and the development of its variants,5,6 now
permits Raman imaging at up to an order of two magnitudes
deeper than previously possible using conventional Raman techni-
ques. SORS therefore enables tissue monitoring through depths of
mm and cm non-invasively.6 This article reviews this rapidly
expanding field from the perspective of biomedical diagnosis,
specifically focusing on progress over the recent years and the
techniques most relevant to the field of medical diagnostics.
Deep-tissue Raman
spectroscopy techniques
SORS and its related concepts have built upon preceding
research and advances in NIR and fluorescence photon diffu-
sion, which was dedicated to investigating photon propagation
mechanisms in turbid media and developing deep probing
approaches for these techniques.7–13 By utilising the inelasti-
cally scattered Raman photons generated as the laser photons
travel through cells and tissues, it is possible to achieve much
higher chemical specificity, broadly on a par with mid-infrared
absorption spectroscopy, which itself cannot be used for deep
probing of living tissue due to the high level of absorption of its
signals by water and other components in tissues. Early
research into the use of Raman spectroscopy for deep probing
in turbid media included time-gated approaches which utilise
the fact that in comparison to shallow born Raman photons,
deeper born Raman photons take longer to emerge at the
surface of a turbid medium.14 These, however, rely on the use
of impulsive Raman excitation and time-gated detection, which
is therefore instrumentally complex and costly. Moreover, the
approach provides relatively moderate gains in depth penetra-
tion and is associated with significant safety issues due to the
impulsive nature of the laser excitation which translate into
restrictions to applicable powers in in vivo applications.
Spatially offset Raman spectroscopy (SORS)
The breakthrough in deep probing of tissue with Raman
spectroscopy emerged with the advent of SORS.5,15,16 The
approach relies on the fact that deeper penetrating photons
statistically tend to migrate laterally from the illumination zone
on the sample surface, in a random walk-like fashion,17 whereas
those photons that have scattered back to the surface from
shallower depths have had less opportunity to travel laterally.
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The typical presence of surface-to-air interfaces accentuates
this effect by preferentially facilitating loss of the photons
propagating through near-surface layers, as any laser photon
reaching the interface is immediately and irretrievably lost.
Collecting Raman photons at the surface of the sample away
from the laser illumination zone therefore biases the detected
signal towards deeper zones within the sample. This is in
contrast with conventional Raman collection geometry, i.e.
back-scattered geometry, where signal would be collected from
the illumination zone itself (Fig. 1A). The separation between
the illumination and collection zones is termed spatial offset Ds
(Fig. 1B) and, the larger the spatial offset, the greater the signal
bias towards the deeper zones.
If the sample is stratified with chemically distinct layers one
can use varying spatial offsets to obtain SORS spectra of
individual layers in a sample, thus enabling the chemical
composition of each separate layer to be elucidated. This is
accomplished by a scaled subtraction of SORS spectra from
each other to cancel the contribution of individual layers6 and
can be carried out in an automated manner without any
knowledge of the composition of each layer. Another means
of accomplishing this is to subject the set of SORS spectra
obtained at different spatial offsets to multivariate analysis.
This can facilitate deconvolution of different layers in a semi-
automated way, e.g. using Principal Component Analysis (PCA)
in combination with Band Target Entropy Minimisation
(BTEM)18–22 to retrieve real spectra of individual layers rather
than their linear combinations that are typically output from a
basic PCA. Recently a more advanced variant has been developed
for specifically retrieving Raman signals from biological samples
(bone in soft tissue) and is termed ‘‘adaptive BTEM’’ (ABTEM).23
Alternatively, the spectral unmixing can be performed using an
overconstrained extraction algorithm based on fitting with
spectral libraries.24 General applications of SORS in biological
areas include the identification of particular biomarkers, or the
quantification of some biological subcomponents relative to
some other measurable Raman entity in the sample.
The basic SORS concept relies on a point-like illumination of
the sample surface and collection of Raman signal from a
point-like zone on the sample surface. SORS collection effi-
ciency can be improved by integrating the signal at the same
offset from the illumination point, i.e. in a circle (Fig. 1C). A
more advanced variant of SORS, which has a particular rele-
vance to biomedical applications is ring illumination SORS
(Fig. 1D).25,26 In this arrangement, the laser illumination zone
is in the shape of a ring and Raman signal is collected from the
centre of this ring, e.g. using optical fibres. The radius of the
illumination ring facilitates the spatial offset. A ring shape
profile of the laser illumination beam is typically generated
using a conical lens (‘axicon’)26 and the radius of the illumina-
tion zone can be varied, for example, by changing the axicon-to-
sample distance. Further, using an axicon in this way leads to
varying ring diameters, but an invariant ring thickness, being
dependent on the beam diameter incident on the axicon lens.
As the larger ring radius brings with it a larger illumination
area, this concept enables the increase of the illumination laser
power for larger spatial offsets to benefit in vivo applications
whereby intensity is typically restricted by permitted laser safety
thresholds. Such an increase of laser power for larger spatial
offsets is highly desired as the larger spatial offset is inherently
accompanied by lower overall detectable SORS signals. This benefits
accuracy of measurement and enhances penetration depths.
Fig. 1 Schematic comparing different SORS approaches with conventional Raman. (A) Conventional backscattering Raman: laser excitation and Raman
photon collection take place at the same point. (B) Conventional SORS: the point of collection is offset from the point of excitation by a spatial offset of
Ds. (C) Ring collection SORS. The Raman photons are collected in a circular array around the point of excitation. (D) Ring illumination SORS: the laser
illumination zone is in the shape of a ring and Raman photons are collected at the centre of the ring. (E) Transmission Raman: the laser excitation and the
Raman collection zone are separated to the extreme. Raman collection takes place on the opposite side to laser illumination.
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Recently, the use of light modulation in SORS imaging facilitated
by micro–electro–mechanical systems (MEMS) was also demon-
strated. The concept permits rapid switching between different
spatial offsets without using moving parts of the system apart
from the MEMS subcomponents themselves.27,28
When planning SORS measurements one must evaluate the
optimum spatial offsets, taking into account the geometry and
optical properties of the sample. There are several approaches
to finding the optimum offset. In general, the accessible depth
typically increases monotonically with increasing spatial offset.
However, the larger the spatial offset, the weaker the Raman
signal typically becomes. Therefore, a balance must be struck
between the two processes to achieve optimum conditions in
order to probe tissues at a specific depth. The goal is to achieve
the highest signal-to-noise (S/N) ratio in the signal retrieved
from a particular (target) layer or depth. This is often accom-
plished empirically by trial and error and by changing various
experimental parameters, e.g. laser power or acquisition time.
Alternatively, one can perform numerical analysis (e.g. photon
propagation simulations) to deduce the expected S/N for a
particular spatial offset. The latter requires the knowledge of
sample optical properties and as such, is a less common
approach compared to the former. The setting of optimum
spatial offset was studied by Maher and Berger29 and Bloom-
field et al.30 The latter study also concluded that for optimum
results, a larger acquisition time should be devoted to acquir-
ing SORS spectra at larger spatial offsets in order to obtain the
highest possible S/N spectra from a target layer or depth.30
With regards to collection of scattered photons, the Raman
signal is often collected from the sample surface using optical
fibres to decouple the sample from the core detection appara-
tus, however free space coupling using collection and imaging
lenses can also be used. The detection is typically facilitated
using a low f-number (high etendue) spectrometer equipped
with a deep depletion CCD (maximising quantum efficiency for
near-infrared (NIR) light) on its output port.31
SORS limitations include restricted penetration depth given
by the experimental conditions and sample specific conditions;
principal SORS geometry and optical properties of individual
layers. In particular, absorption can severely limit accessible
depths and is therefore a particular consideration in medical
applications. For this reason, SORS measurements are typically
performed using a NIR laser excitation (e.g. 785, 808 or
830 nm), within the NIR optical window for tissue, to ensure
minimum laser and Raman photon absorption.6,32,33 Other
restrictions on SORS use includes interference from sample
fluorescence which can be particularly severe with darker
tissues (e.g. with liver or higher melanin pigmentation in skin)
or due to the presence of hair on the sample (especially if it is of
a darker colour). The latter, however, can be mitigated by
shaving the probed area.34 The fluorescence generated due to
the pigmentation associated with darker skin complexions can
also be reduced by introducing spatial offsets since it is con-
fined to surface layers where melanin resides when probing deeper
layers. In analogy with the relative reduction in the Raman signal
from the surface when using SORS, the surface fluorescence signal
is also suppressed relative to subsurface signal from the same
layer by introducing spatial offsets.35,36 Alternative approaches
include time gated fluorescence suppression.37–40
Micro-SORS
The use of micro-SORS which combines SORS with microscopy
to probe very thin layers on a micrometre to sub-mm scale has
also been demonstrated. The technique has been applied
extensively to the analysis of paint in cultural heritage and also
exemplified in analysis of wheat seeds and in other areas.41–44
The technique of micro-SORS is mentioned here for complete-
ness as it is reasonable to assume that studies involving
humans would require the probing through larger thicknesses
than what can be achieved using micro-SORS. However, micro-
SORS could be beneficial for probing very thin interfaces such
as skin in dermatology at depths beyond the reach of conven-
tional confocal Raman microscopy, or with smaller animal
models. This could also be advanced through the development
of ‘‘flexible’’ Raman instrumentation to enable sampling of
areas of the body which are otherwise difficult to reach.45
Transmission Raman
‘‘Transmission Raman Spectroscopy’’ (TRS),46 in which the
laser excitation area and Raman collection area are located
on opposing sides of the sample, can also be considered an
extreme case of SORS (Fig. 1E). The technique can only be
applied when access to the two sides of sample is available and,
importantly, where sample thickness permits Raman signals of
adequate quality to be acquired. Unlike SORS, in its simplest
form, TRS does not permit the separation of sample layers from
each other. It instead enables an approximation of a volumetric
Raman signal to be obtained. Although TRS was demonstrated in
very early days of Raman spectroscopy its utility in the medical
field has only recently been recognised and exploited.6,47,48
Surface enhanced spatially offset Raman spectroscopy
(SESORS)
Another biomedically relevant variant of SORS is ‘‘surface-
enhanced spatially offset Raman spectroscopy’’ (SESORS), a
technique which combines the depth penetration capabilities
of SORS with the signal enhancing benefits of SERS to generate
Raman signals through depths far greater than what can be
achieved using traditional SERS imaging. SESORS has previously
been shown to access depths of B5 cm in biological tissues, thus
providing exceptional depth sensitivity and selectivity.49,50
In order to carry out SESORS measurements, SERS-active
nanoparticles (NP’s) must first be synthesized from a metallic
NP, typically gold, which is then functionalized with a Raman
reporter molecule.51 SERS relies on the interaction between the
analyte (e.g. Raman reporter molecule) and the localised sur-
face plasmon resonance (LSPR) asscoiated with the metallic
NP onto which the analyte is adsorbed. Following interaction
with incident light, oscillation of the conduction band elec-
trons takes place which increases the local field experienced by
the NP. In turn, this induces greater polarisation of the analyte
molecule and thus further enhancement in Raman scattering
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consequently observed.52 Moreover, by functionalizing the
metallic NP with a reporter molecule that is in resonance with
the wavelength of incident light, it is possible to achieve
enhancements in signal by even greater orders of magnitude
(1010–1014).51,53–55 This is referred to as ‘‘surface enhanced
resonance Raman scattering’’ (SERRS). Although intravenous
administration of the SE(R)RS NPs into a living subject is an
invasive procedure, imaging of the accumulation of SE(R)RS
NPs at the site of interest by means of SORS is non-invasive and
can also be carried out repeatedly.54 In addition, SESORS
measurements have also been performed through the use of
a metallic micro-substrates implanted subcutaneously to
enable repeated measuring of blood glucose levels.56 It is also
possible to engineer SE(R)RS NPs to specifically accumulate at
the site of interest in vivo through the use of targeting ligands
such as antibodies57–60 or peptides.61 In this instance the
SE(R)RS NPs are typically encapsulated in a silica shell prior
to biomolecule functionalization, (Fig. 2).55 This is of interest in
diseases such as cancer in which SE(R)RS NPs have been shown
to specifically target biomarkers that are over-expressed on the
surface of tumour cells.34,61,62 As such, SESORS is a promising
technique which can offer, deep, molecularly specific, non-
invasive in vivo imaging.
Special techniques (temperature, pH and depth)
Various other derivatives of the above methods have also been
introduced in recent years which enable the monitoring of
other sample parameters rather than just chemical composi-
tion. These include temperature (T) and pH sensing as well as
depth determination of an inclusion within a turbid matrix.
For example, the monitoring of temperature can be achieved
by utilizing a combination of Stokes and anti-Stokes measure-
ments to detect changes in the temperature of a target (e.g.
SE(R)RS NPs). Such an approach has been demonstrated with
single SERS NPs,63 and more recently through greater depths
using SESORS with both reporter NPs and photothermal gold
nanoshells.64–66
In some applications it is also desirable to localise the target
(e.g. lesion) in a matrix (e.g. tissue). This can be achieved, in
part, by moving the sample in the x and y directions and
maximising SORS or TRS signals. However, determining the
specific depth of a target in the z-direction is more challenging.
Recently, a simple yet effective concept relying on differing
absorption of two (or more) Raman bands of the lesion by the
surrounding matrix was demonstrated and can be applied to
samples with or without SERS NPs.65 The deeper the phantom
lesion is located within the tissue, the longer the propagation
distance of emerging Raman photons at tissue surfaces (points
of collection). Moreover, longer propagation distances result in
larger relative Raman band intensity distortion of the target
signal due to tissue differential absorption.67,68 This is a result
of water and/or lipids absorbing the two monitored Raman
bands differently. The application of these special techniques
for the monitoring and assessment of depth, pH and tempera-
ture are discussed in the ‘‘Applications’’ section below.
Applications
Although the SORS technique is currently not approved for
general diagnostic use in patients, significant advancements in
this area have been made with the aim of eventually translating
this technique into the clinic. In this section, we will discuss
recent examples in which SORS has been applied to solving
medically related problems within the last five years.
Assessment of blood quality
In combination with SERS substrates, one of the first practical
applications of the SESORS technique was for the non-invasive
monitoring of blood glucose levels in vivo.56,69 Recent advances
have also shown that SORS can be applied to other blood-
related questions, specifically the quality assessment of red
blood cells for patient transfusion. Typically, following dona-
tion and separation into different components, red blood cell
concentrates can be stored for up to 42 days before they must
be discarded due to concerns over biochemical changes.70,71 By
utilizing SORS, Vardaki et al., demonstrated that it is possible
to profile changes in oxygenation over the 42-day storage
period. It is well understood that over time, the chemical
composition of blood units from each donor changes at differ-
ent rates, thus the age of the unit does not provide certainty
with regards to red blood cell quality.71 Importantly, SORS
analysis provided a means to non-invasively monitor and
provide useful chemical information on the quality of blood
at a particular time, e.g. prior to transfusion, without compro-
mising the usability of the unit. These results demonstrate the
suitability of SORS to facilitate quality-control in blood-banks.
Assessment of bone diseases
Since the first demonstration of SORS in 2005, one area that
has seen intense investigation in recent years is the use of SORS
for the non-invasive assessment of bone disorders such as
osteoporosis.25,35 Currently, the clinical standard for measur-
ing bone density is by dual X-ray absorptiometry (DXA) which
measures areas of low bone mass and thus identifies patients
with increased fracture risks.72,73 However, such an approach
has been shown to be a poor indicator of low bone mass in
Fig. 2 Conceptual figure outlining the design of SE(R)RS NPs for in vivo
applications. SE(R)RS NPs typically consist of a gold core, e.g. star which is
then functionalised with a Raman reporter molecule and encapsulated in a
thin silica shell. Active targeting is achieved through the use of a specific
targeting ligands such as antibodies.
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certain circumstances, e.g. early postmenopausal women,72,74
and in addition, requires the use of ionizing radiation. More-
over, DXA is unable to measure the organic component of bone,
mainly collagen, meaning, at least in part, that around 30–40%
of fracture risks go undetected.25 Quantitative CT can be used
as an alternative since it is able to provide volumetric and
stress–strain information, however in comparison to DXA, it is
associated with significantly higher levels of radiation and
greater financial costs.72 Thus, due to its lack of ionizing
radiation, low cost and ability to provide information on both
the inorganic and organic component of bone (mineral and
collagen respectively), SORS has been explored as a promising
alternative.
A SORS tomographic instrument was designed in which
excitation and collection fibers were assembled in a 360-
degree plane around the sample of interest. In combination
with microCT, this arrangement of fibers enabled the transcu-
taneous tomographic Raman imaging of intact rat tibia.75 As
well as the use of microCT,75 other reports have also high-
lighted the benefit of combining SORS with other imaging
modalities such as optical coherence tomography (OCT),76 to
help support the obtainment of morphological and molecular
information from deeper layers of biological samples. Feng
et al., applied SORS to measure subcortical bone tissue and
biochemical changes through increased depth using intact
murine bones.77 Importantly, the same approach was later
applied to predict bone strength transcutaneously, in vivo.78
Using partial least squares (PLS), it was possible to predict area
mineral bone density, volumetric bone mineralization density
and maximum torque of each tibia as quantified ex vivo using
DXA, microCT and biomechanical tests respectively. Although
several reports have successfully demonstrated the potential of
SORS to identify changes in both the organic and inorganic
component of bone, it is extremely important to understand the
precise depth at which particular Raman photons are generated
in order to correctly assign any observable changes to the
surface or sub-surface sample components. This is vital if SORS
imaging is to translate into the clinic. Sowoidnich and co-
workers performed studies to evaluate the sampling depth of
a SORS set up with bone samples using segmented bones and
inserting a thin interlayer at different depths.79–81 Investigation
into the influence of bone mineralization on photon migration
properties from ex vivo bone samples with varying levels of
mineral density revealed that photons can more easily migrate
inside less mineralized bone. The maximum accessible sam-
pling depth was also found to be dependent on the bone
mineralization levels, therefore in comparison to the healthy
controls, Raman signals could be detected through greater
thicknesses of less mineralized, unhealthy bone.79
Buckley et al., reported the potential of SORS to detect
differences in the mineral component of bone in fractured
and non-fractured controls. The results demonstrated that
fractured femora were 5–10% more mineralized than non-
fractured controls.82 The ‘mineralisation term’ refers here to
the ratio of mineral to collagen which was measured to be
higher for fractured bones. This is in line with expectations,
as less minerals compared to collagen makes the bone matrix
more brittle. Recently, the use of adaptive-band targeted
entropy mineralization has been applied to spectral un-
mixing of SORS spectra from bone samples buried beneath
tissue.23 The algorithm was successfully applied to transcuta-
neous SORS spectra and represents a step towards development
of an optimized clinical SORS system, specific for diagnosis of
bone disease in patients.
Using a programmable digital micro-mirror device (Fig. 3A)
to collect or reject light at spatial positions in a 2D plane, Liao
et al., developed a fast method of setting spatial offsets in SORS
measurements of diverse shapes.83 This was then applied to the
non-destructive characterization of bone tissue engineering
scaffolds, (Fig. 3B–F).27 Optimization was achieved using a
series of phantoms to mimic the mineralization of scaffolds
implanted in a critical bone defect of a large animal, and to
further understand the measurement conditions required for
an in vivo longitudinal study. Such a concept represents a
promising approach towards the longitudinal monitoring of
engineered bone scaffold mineralization and bone re-growth
in vivo.84,85
Monitoring of changes in temperature and pH
The determination of temperature is particularly relevant to
photothermal therapy (PTT) applications, where currently no
practical method exists for reading subsurface temperatures of
SERS NPs mediating PTT and surrounding tissue.86 To date,
PTT is performed without any real time feedback on tempera-
ture changes taking place through significant (4few mm)
depth. Moreover, temperature is highly dependent on sample
geometry and the optical properties of both the medium, e.g.
tissue and the photothermal material, e.g. NPs, thus making it
difficult to control. However, since SORS accounts for sample
geometry and optical properties, the combination of Stokes
with anti-Stokes measurements can therefore enable monitor-
ing of temperature changes in an analyte (e.g. SERS NPs).64,66
Surrounding bulk tissue temperature can also be monitored by
measuring directly the Stokes and anti-Stokes bands or those of
SERS NPs labelled or assembled in such a way so that they do
not absorb and mediate the heat transfer from the laser heating
source. A proof-of-concept study has also demonstrated that it
is possible to monitor pH deep within tissue by monitoring the
position of a SESORS band of NP’s labelled with molecules
exhibiting Raman band position pH-dependency.87 More
recently, a similar approach showed that it was possible to also
precisely predict the depth at which SERS NPs were buried in a
turbid phantom (0.5% intralipid) and simultaneously monitor
changes in pH of the media surrounding the NPs.88
Detection of neurotransmitters
Neurotransmitters are a class of chemical messengers which
transmit signals across a chemical synapse from one neuron to
another target neuron, muscle cell or gland cell.89 They play a
critical role in maintaining human health and any imbalance
can cause serious mental or physical health conditions includ-
ing schizophrenia and Parkinson’s disease. Currently, there is a
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need to establish more rapid, effective methods capable of
quantifying neurotransmitter concentrations in vivo. With this
in mind, SESORS has since been utilized for the measurement
of melatonin, serotonin and epinephrine at concentrations as
low as 100 mM in a brain tissue mimic through a cat skull.90
Using an inverse SORS approach, the ex vivo detection of SERS
NP through a monkey skull has also been reported.91 More
recently, Sharma and colleagues reported the ability to resolve
spectral signatures from individual neurotransmitters and
mixtures of neurotransmitters at physiologically relevant con-
centrations using inverse (ring illumination) SORS. This was
achieved using agarose gel which was then embedded within
the ex vivo rat skull to create a brain tissue mimic. Using these
phantoms, SESORS established limits of detection for a range
of neurotransmitters at physically relevant concentrations;
melatonin (100 nM); serotonin (400 nM); dopamine (1 mM);
norepinephrine (400 nM); and epinephrine (800 nM).92 In
addition, the brain of a sacrificed mouse was spiked with
serotonin and gold NPs to demonstrate the potential of SESORS
to detect neurotransmitters through the skull, (Fig. 4).92 This
represents an notable step towards the use of SESORS for the
in vivo detection and continual monitoring of varying concen-
trations of neurotransmitters in a living system. However, it is
important to note the challenges associated with the detection
of low concentration species directly using SESORS in vivo. This
is in part, due to complex nature of biological fluids in which
several components, e.g. proteins, will compete with the neuro-
transmitters in order to bind to the gold NP surface.
Cancer diagnostics using SORS
Owing to its ability to provide chemically specific information
in a non-invasive manner, previous work has demonstrated the
applicability of SORS and transmission Raman for the non-
invasive detection and characterization of cancerous lesions.93
With the exception of skin cancer, breast cancer is the second
most common cancer to affect women the United States94,95
and screening is typically performed using mammography (low
energy X-rays) to locate tumors inside the breast.96 MRI may
also be used to screen women who are associated with a higher
risk of breast cancer however both imaging techniques are
associated with false positives. In addition, they also fail to
Fig. 3 Representative images of 3D printed bone scaffolds. (A) Graphical
drawing of the DMD-based SORS instrument used to image the bone
scaffolds. Abbreviations are as follows; OBJ, objective; IOM, inverted
optical microscope; MSC, microscope side-port camera; DCM, dichroic
mirror; LCF, laser clean filter; NDL, 20 mW, 532 nm Nd:YAG diode laser;
DMD, digital micro-mirror device; DRC, DMD inspection camera; NF,
notch filter; SP, spectrometer; CCD, charge couple device detector. The
red circles in the magnified images (i) and (ii) refer to the position
corresponding to the focused laser on the sample, and on the sample-
conjugate plane of the DMD (equivalent to a zero spatial offset). (i) Displays
a DMD pattern for a standard confocal Raman measurement and (ii) shows
a possible SORS configuration. (B) Micro-CT 3D reconstruction image of
polycaprolactone (PCL) and hydroxyapatite (HA) scaffold PCL : HA 1 : 4 with
dimensions 10  10  5 mm, porosity = 64.7%. (C) Images from dissecting
microscope of a PCL : HA (1 : 4) scaffold (D) scanning electron microscopy
of a PCL : HA scaffold with 1 : 2 blend ratio. (E) Conceptual diagram of the
head of a femur with a critical defect drilled into it. The scaffold is then
inserted into the defect. (F) Conceptual close up of the bone defect filled
with a PCL scaffold. Adapted from ref. 83 and 84 with permission from The
Optical Society, copyright 2016 and 2019.
Fig. 4 Ex vivo detection of 100 mM serotonin through the skull of a mouse
using SESORS. A SORS spectrum of the mouse brain through the intact
skull without the injection of serotonin or gold NPs (top spectrum, blue). A
SESORS spectrum of the mouse brain following the injection of 100 mM
serotonin at a 0 mm offset (red) and a 1 mm offset (green). The SORS
spectrum of the mouse brain before the injection of NPs was subtracted
from the offset spectra. Data was acquired using a laser wavelength of
785 nm, 90 mW, t = 120 s. The SERS spectrum of 100 mM serotonin on
AuNPs at pH 2, 785 nm, 5 mW, t = 30 s (purple). Reproduced from ref. 92
with permission from the Royal Society of Chemistry, copyright 2020.
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provide molecularly specific information meaning that invasive
biopsies must be performed in order to confirm the disease
status which results in increased patient anxiety and costs.
Two major types of microcalcifications are found in breast
tissue: calcium oxalate dihydrate (type 1) and calcium phos-
phates, mainly calcium hydroxyapatite (type 2) with the latter
resulting from cellular degradation or necrosis and is thus
associated with a higher likelihood of malignancies.97 Raman
spectroscopy has been shown to chemically identify differences
in benign and malignant microcalcifications of the breast and
SORS and transmission Raman has since been applied to
identify such calcifications at clinically relevant depths.93,98,99
Previous research into this application reported the possibility
to detect hydroxyapatite at clinically relevant concentrations
through a depth of 20 mm,98 however more recently, optimiza-
tion of instrumentation (Fig. 5) enabled detection of clinically
relevant concentrations of hydroxyapatite through a depth of
40 mm.31 This was achieved by increasing the power of the
incident laser through use of a larger spot size, improving the
efficiency of the spectrograph by increasing the slit width and
utilizing a grating with a high dispersion to improve spectral
resolution. These results have helped drive the translation of
this technique into the clinical settings with this approach now
moving towards trials in humans.100
Thomas et al., evaluated the feasibility of a 3-dimensional
(3D) scanner to assess the entire margins of a resected speci-
men within a clinically feasible time.101 Building on a previous
design by Keller et al.,102 the authors designed a 7 mm diameter
probe that enclosed 36 detector fibres (100 micron in diameter)
organised into 4 quadrants.101 The 36 fibres were then aligned
into a single line at the spectrograph input. In comparison to
the previous probe design which contained only 10 fibres,102
the new design contained 36 optical fibres and therefore
facilitated approximately four times faster collection of Raman
photons with the same S/N ratios. Furthermore, in comparison
to previous work, it was possible to acquire Raman signal from
a larger surface area of 38.5 mm2, thus enabling the probe to
cover the entire specimen surface over a shorter period of time.
Using breast tissues excised from prophylactic mastectomy
specimens and a classical least squares algorithm, areas of
the specimen were assessed and margins were classified either
as fatty or fibroadenomatoid (Fig. 6A, B, D, and E). 3D images of
the sample obtained using depth-averaged Raman imaging were
also in agreement with histopathological staining, (Fig. 6C and F).
The results demonstrate the suitability of a SORS-based probe to
carry out depth-averaged Raman imaging for the assessment of
biochemical margins of disease.
Cancer diagnostics using SESORS
SORS provides a means of detecting the chemical signatures of
diseased tissue through depth in a non-invasive manner. More-
over, it is widely accepted that if the intended application is to
detect Raman signals at the site of interest through depth,
SORS offers a clear advantage over traditional Raman imaging
approaches.103,104 In addition to SORS and in combination with
SERS NPs, SESORS imaging has also been explored for the
detection of disease through tissues. In this instance, however,
it is not the spectral signatures of the diseased tissue that are
detected, but instead the molecularly specific ‘‘fingerprint’’
spectra of the Raman reporter molecules functionalized to
the surface of metallic NPs, namely gold.
For the detection of diseases such as cancer, SESORS relies
on the accumulation of SERS NPs at the site of interest, e.g.
tumor. Using ex vivo MCF7 multicellular tumor spheroids
(MTS) as 3D tumor models of breast cancer, the detection
of SERRS NPs which had accumulated inside MTS through
depths of 15 mm was demonstrated (Fig. 7A and B).105 In this
instance MTS were buried beneath porcine tissue phantoms
and mapped using a handheld SORS spectrometer to demon-
strate the potential suitability of handheld SORS instrumenta-
tion for use in the clinic. The advantage of using resonant
chalcogenpyrylium-based Raman reporters to generate high
Raman scattering through depth was also shown, enabling the
authors to report the application of ‘‘surface-enhanced spatially
offset resonance Raman spectroscopy’’ (SESORRS) for the first
time.105 Using the same set-up, the ability to spectrally distinguish
Fig. 5 Conceptual figure describing the transmission Raman experimental set-up. Reproduced from ref. 31 with permission from John Wiley & Sons,
copyright 2018.
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between multiple SERRS NPs within MTS was also explored.106
Through the application of PCA it was possible to not only
detect but classify multiple vibrational fingerprints through a
depth of 10 mm (Fig. 7C and D). Reference spectra were
obtained from aqueous solutions of SERRS NPs containing
each of the three single SERRS NP flavours and a mixture
composed of equal amounts of each solution (triplex), obscured
behind 10 mm of porcine tissue. Moreover the benefit of using
resonant Raman reporters for SESORRS has also been shown
to improve limits of detection.107 In comparison to the non-
resonant Raman reporter molecule 1,2-bis(4-pyridyl)ethylene
(BPE), NPs functionalized with resonant chalcogenpyrylium
reporter molecules can be detected at much lower concentrations
using SESORRS. In this report, calculated limits of detection
Fig. 6 3D margin assessment of breast specimens using automated depth-averaged Raman spectroscopy. (A) Photograph of the breast specimen which
includes fatty margins. (B) Margins of the specimen as rendered by the 3D-scanner. (C) H&E section from a biopsy spot taken from the fatty margin
(10 magnification). (D–F) Describe the corresponding figures for a breast specimen with fibroadenomatoid margins. (F) An increase in fibro-epithelial
composition can be observed at a depth of 0.5–1.5 mm from the margin. Reproduced from ref. 101 with permission from Nature Research, copyright 2017.
Fig. 7 (A and B) A false colour xy-2D heat SESORRS map of MTS containing SERRS NPs through 15 mm of tissue using a handheld spectrometer.
Mapping was performed using a 3 mm step size to create an image of 7  7 pixels. (C and D) PC scores plots discriminating between single SERRS NP
flavours and a triplex of all three SERRS flavours within (C) MTS and (D) solution through 10 mm of porcine tissue. Distinct separation is observed in both
score plots. All measurements were carried out using a 2 s integration time, 5 accumulations, 830 nm laser excitation wavelength. Adapted from ref. 105
and 106 with permission from the Royal Society of Chemistry, copyright 2018.
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indicated that such SERRS nanotags stored in a glass cuvette
and obscured by 5 mm of tissue could be detected at concen-
trations as low as 104 fM using SESORRS.107
In these instances, however, the SERRS NPs were buried at
specific depths, meaning that the Raman signals acquired from
the SERRS NPs were detected from known and predetermined
depths. To date, the ability to precisely determine the specific
depth at which SERRS NPs are located without any prior
knowledge remains a significant challenge and the means
to do so is especially important for in vivo applications where
SERRS NPs will be distributed at different and unknown
depths, e.g. within a cancerous lesion.108 Using SORS and
transmission Raman, Mosca et al, recently reported a viable
and robust method capable of predicting the depth of both a
single buried object and SERRS NPs through turbid phantoms
by monitoring the relative intensity of two Raman bands
exhibiting differential absorption by the matrix (Fig. 8).67,68 A
proof-of-concept study demonstrated possibility of achieving
better than B10% accuracy of determining the depth of a
buried target relative to the overall sample thickness in SORS
and TRS measurements.67 The results demonstrate a potential
effective means of calculating the depth at which SERRS NPs are
localized in vivo as well as determining the optimum distribution
of laser radiation around a sample in PTT applications.68
Several reports in the literature have also discussed the
potential of SESO(R)RS to image disease, specifically cancer,
however, until recently, this approach was only applied to
ex vivo phantoms and not to a living system, i.e. in vivo. To
address this, Nicolson et al., demonstrated the ability to image
glioblastoma multiforme (GBM) in living mice, non-invasively,
using the SESORRS technique (Fig. 9A).34 Using a transgenic
mouse model, which presents with all the histopathological
and imaging hallmarks of human high-grade gliomas, the
authors used cyclic RGD peptides to actively target and thus
image GBM in vivo through the intact skull. A classical least
squares fit was used to support image analysis and generate
SESORRS images that outlined the tumors with high precision.
SESORRS images (Fig. 9C) were in agreement with magnetic
resonance images (Fig. 9B) taken prior to the injection of
SERRS NPs, as well as ex vivo histology (Fig. 9D–F).34 Not only
is this work the first demonstration of SESORRS for the in vivo
imaging of any disease, it also represents an important step
Fig. 8 Prediction of paracetamol depth in a turbid matrix using conventional
SORS and transmission Raman measurements. Results show conventional
SORS and transmission Raman predicted vs. measured depth of parace-
tamol buried at depths of 3, 9 and 12 mm. Measurements were acquired
using 20 s integration time, 5 accumulations and a laser output power of
200 mW (830 nm). Reproduced from ref. 67 with permission from the
American Chemical Society, copyright 2019.
Fig. 9 In vivo SESORRS imaging of glioblastoma multiforme through the intact skull of mouse. (A) Conceptual figure demonstrating the SORS set-up.
(B) 2D axial T2-weighted MRI taken 4 weeks post injection of DF-1 cells which induce the growth of GBM in vivo. MRI confirms the presence of a left
frontal tumour (outlined in red). MR Images were acquired using a slice thickness of 0.7 mm taken at a depth of 3.6 mm. (C) The SORS heatmap of the
SERRS NPs was superimposed onto the SORS heat map of bone with the SESORRS image delineating the tumour margin in agreement with the MR image.
(D) H&E stained 5 mM section of the brain. The arrows correspond to areas of the slice which represent healthy tissue (E) and unhealthy tissue (F). Images in
(E and F) were taken at 40magnification. SORS measurements were acquired by utilizing a power density of 13.8 mW mm2 (785 nm), a spatial offset of
2.5 mm, 3 s integration time, 5 acquisitions. Reproduced from ref. 34 with permission from Ivyspring International Publisher, copyright 2019.
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towards the clinical translation of SE(R)RS NPs by demonstrating
the ability to detect them in vivo through depths far superior to
traditional Raman imaging methods. Using subcutaneous
models, previous work has demonstrated the use of traditional
Raman mapping to detect both single and multiple flavours of
SE(R)RS NPs simultaneously in vivo.54,57,58,109,110 In these
instances, however, the tumours were located at shallower depths.
We therefore envisage that due to the ability of SESO(R)RS to
probe through greater depths and thus detect deeper-seated
tumours, we will see an increasing number of research groups
utilizing this technique for a wide range of pre-clinical imaging
applications. Specifically with regards to cancer imaging, we
encourage the development of brighter SE(R)RS NPs as well as
strategies which will enable greater NP accumulation within the
tumour microenvironment. This can be achieved by recogniz-
ing tumours as complex and heterogeneous structures, rather
than simply as a leaky sponge in which NPs will accumulate
following prolonged circulation in vivo. Consideration of the
above, as well as a number of other factors, will also help to
reduce off-target accumulation and potential long-term toxicity
in vivo.111
Conclusion and outlook
In recent years, the suitability of conventional SORS and
transmission Raman for the non-invasive analysis of disease
has advanced to an extremely exciting level. In this review we
have discussed the use of SORS for the detection of bone
disease, neurotransmitters and cancer, however, in the future,
we envisage that the application of SORS and SESO(R)RS
imaging will not remain exclusive to these three areas. We are
particularly excited by the prospect of using SESO(R)RS as a tool
to complement the limitations associated with other clinically
approved molecular imaging techniques. Whilst we note the
translation of SESORS into the clinical setting is highly depen-
dent on the approval of SE(R)RS NPs by regulatory bodies,
such as the Food and Drug Administration (FDA), we believe
that advances in SESO(R)RS imaging will help to achieve such
approval. Moreover, we anticipate that the field will see a
greater shift towards the use of SORS over conventional Raman
for applications involving preclinical and clinical imaging. This
will be supported through advancements in Raman instrumen-
tation and, in the case of SESO(R)RS, through the development
of brighter and safer SER(R)S NPs.
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